Revised risperidone PBS listings for behavioural and psychological symptoms of dementia from 1 January 2020
Page last updated: 29 November 2019
Commencing 1 January 2020, the Pharmaceutical Benefits Scheme (PBS) listings for risperidone for the treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) of the Alzheimer type will change.
This change involves the addition of a new ‘continuing’ listing that is Authority Required (Telephone). This listing will allow prescribers to treat BPSD with risperidone, beyond 12 weeks of ‘initial’ therapy, when appropriate.
For more information on these changes please view the Risperidone Factsheet.